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1. Introduction
An understanding of the epidemiology of multidrug resistant tuberculosis (MDR-TB) and the
extensively drug-resistant tuberculosis (XDR-TB) is critical for effective control of the global
burden of tuberculosis (TB) which is caused by the organisms belonging to the Mycobacterium
tuberculosis complex. Epidemiology of MDR-TB and XDR-TB will be reviewed here.
The history of tuberculosis treatment has observed sequential development of resistance to
anti-tuberculosis drugs over the decades. Para amino salicylic acid (PAS) and isoniazid (INH)
were introduced to reduce the development of streptomycin (SM) resistance, which heralded
the era of combination treatment for tuberculosis [1]. Within 20 years, resistance to both INH
and SM was already a challenge in the use of INH, SM and PAS as the standard anti-tubercu‐
losis regimen. With the discovery of rifampicin (RMP) in 1966 [2] and the expansion of its use
between 1970 and 1990, patients who were already carriers of isoniazid (INH) resistant
Mycobacterium tuberculosis strains became resistant to RMP. This was the start of a progressively
growing problem, multi drug resistant tuberculosis (MDR-TB), which has reached epidemic
proportions in some countries. In the last two decades, with the misuse of other drugs with
anti-tuberculosis action, in particular the fluoroquinolones (FQs), the most effective among the
second-line drugs, resistance has dramatically increased to extensively drug-resistant TB
(XDR-TB) which is defined as resistance to at least RMP and INH (the definition of multidrug-
resistant tuberculosis (MDR-TB)), in addition to any fluoroquinolone, and at least one of the
three injectable anti-tuberculosis (TB) drugs capreomycin, kanamycin and amikacin [3].
1.1. Epidemiology
John Last  has defined epidemiology as “The study of the distribution and determinants
of  health-related  states  or  events  in  specified  populations,  and  the  application  of  this
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study to the control of health problems” [4]. Epidemiologists are concerned not only with
death,  illness and disability,  but also with more positive health states and,  most impor‐
tantly, with the means to improve health [5]. Epidemiological studies are classified as ei‐
ther  observational  or  experimental.  Various  methods  can  be  used  to  carry  out
epidemiological investigations: surveillance and descriptive studies are used to study dis‐
tribution while analytical studies are used to study determinants.
The two mostly common terms used in epidemiology are the ‘prevalence’ and the ‘incidence’.
The incidence of disease represents the rate of occurrence of new cases arising in a given period
in a specified population, while prevalence is the frequency of existing cases in a defined
population at a given point in time [5]. These are fundamentally different ways of measuring
occurrence, and the relation between incidence and prevalence varies among diseases [5]. [For
a comprehensive study on epidemiology, please refer the World Health Organization (WHO)
manual on Basic Epidemiology].
1.2. Epidemiology of tuberculosis
Despite the availability of highly efficacious treatment for decades, TB remains a major global
health problem. In 1993, WHO declared TB a global public health emergency, at a time when
an estimated 7–8 million cases and 1.3–1.6 million deaths occurred each year. In 2010, there
were an estimated 8.5–9.2 million cases and 1.2–1.5 million deaths from TB [6]. According to
the newest report, has observed a gradual decline in the absolute number of TB cases since
2006 and also in the incidence rates of TB since 2002 [6].
2. Global epidemiology of MDR-TB
2.1. Global epidemiology of MDR-TB (global tuberculosis control: WHO report 2011)
Globally, around 50 000 cases of MDR-TB were notified to WHO in 2010, mostly by Eu‐
ropean countries and South Africa. This represented 18% of the 290 000 (range, 210 000–
380  000)  cases  of  MDR-TB estimated  to  exist  among  patients  with  pulmonary  TB  who
were  notified  in  2010.  The  proportion  of  TB  patients  estimated  to  have  MDR-TB  that
were actually diagnosed was under 10% in all of the 27 high MDR-TB countries outside
the European Region, with the notable exception of South Africa where 81% of estimated
cases were diagnosed. In, 15 high MDR-TB burden countries in the European Region, the
proportion  of  estimated  cases  that  were  diagnosed  ranged  from  24%  (in  Tajikistan)  to
over 90% of cases (in Belarus and Kazakhstan); no data were reported from Lithuania. In
Russian Federation,  which ranks third in terms of  estimated numbers of  cases of  MDR-
TB at the global level, the proportion of estimated cases that were diagnosed was 44% in
2010.  The  numbers  of  patients  diagnosed  with  MDR-TB and started  on  treatment  with
recommended second-line drug regimens in the high MDR-TB burden countries in 2010,
at just under 40 000, was less than the number of cases notified [6]
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2.2. Regimen surveys and definitions of patients registration groups for treatment of
tuberculosis
‘Regimen surveys’ measure first-line and/or second-line drug resistance among a group of
selected patients that cannot be considered representative of a patient population [7]. These
surveys help to determine the predominant patterns of drug resistance, and are useful in
providing guidance on appropriate regimens for MDR-TB treatment for particular patient
groups. These include return cases after treatment failure, chronic cases and symptomatic
contacts of MDR-TB cases. According to WHO, Regimen surveys should be conducted in the
process of developing MDR-TB treatment programmes, or within selected centres or diagnos‐
tic units that regularly address high-risk cases.
The fourth edition of WHO Guidelines for treatment of tuberculosis defines patient registration
groups by history of previous treatment [8]. [For a comprehensive study on definitions, please
refer the document WHO/HTM/TB/2009.420].
2.2.1. New case
For the purpose of surveillance, a ‘new case’ is defined as a newly registered episode of TB in
a patient who, in response to direct questioning denies having had any prior anti-tuberculosis
treatment (for up to one month), and in countries where adequate documentation is available,
for whom there is no evidence of such history. Determining the proportion of drug resistance
among new cases is vital in the assessment of recent transmission.
2.2.2. Previously treated case
For the purpose of surveillance, a ‘previously treated case’ is defined as a newly registered
episode of TB in a patient who, in response to direct questioning admits having been treated
for TB for one month or more, or, in countries where adequate documentation is available,
there is evidence of such history.
2.2.3. Primary resistance
Patients with TB resistant to one or more anti-tuberculosis drugs, but who have never been
previously treated for TB, are said to have “primary resistance” (or “initial resistance”) due to
transmission of a drug-resistant strain.
2.2.4. Acquired resistance
Patients diagnosed with TB who start anti-tuberculosis treatment and subsequently acquire
resistance to one or more of the drugs used during the treatment, are said to have developed
“acquired resistance”. In the past, resistance among previously treated cases (defined as cases
with ≥ one month history of treatment) was used as a proxy for acquired resistance; however,
this patient category is now known to also be comprised of patients who have been re-infected
with a resistant strain, and patients who were primarily infected with a resistant strain and
subsequently failed therapy or relapsed.




A patient who has completed a course of anti-TB treatment according to programme protocol
and has at least five consecutive negative cultures from samples collected at least 30 days apart
in the final 12 months of treatment. If only one positive culture is reported during that time,
and there is no concomitant clinical evidence of deterioration, a patient may still be considered
cured, provided that this positive culture is followed by a minimum of three consecutive
negative cultures taken at least 30 days apart.
2.2.6. Failed
Anti-TB treatment will be considered to have failed if two or more of the five cultures recorded
in the final 12 months of therapy are positive, or if any one of the final three cultures is positive.
Treatment will also be considered to have failed if a clinical decision has been made to
terminate treatment early because of poor clinical or radiological response or adverse events.
These latter failures can be indicated separately in order to do sub-analysis.
3. Surveillance studies for the assessment of resistance rates and the
detection of MDR-TB
MDR-TB poses a therapeutic challenge and is associated with increased mortality. Surveillance
studies for the assessment of resistance rates and the detection of MDRTB are therefore crucial
in order to optimize empiric drug therapy and to prevent the dissemination of resistant strains
in a community [9]. The extent of the problem of MDR-TB has been examined by the WHO in
cross-sectional surveys of drug resistance in either clinical series or whole-country cohorts [10].
Cross-sectional surveys almost certainly underestimate the burden and number of cases of
MDR-TB because they do not take into account the numerical burden of TB in the high-burden
countries [11]. When the exercise is repeated with a mathematical modeling design using drug-
resistance estimates and the number of cases of TB, a more accurate picture of the global MDR-
TB burden is claimed [12].
3.1. Global project of drug resistance surveillance
The WHO and the IUATLD (International Union against Tuberculosis and Lung Disease) have
established a global project of drug resistance surveillance that is based on standard epide‐
miological methods and quality control through an extensive network of reference laborato‐
ries. The Global Project has served as a common platform for country, regional and global level
evaluation of the magnitude and trends in anti-tuberculosis drug resistance quantified the
growing global burden of MDR-TB and started to document the spread of XDR-TB. Since its
launch in 1994, the Global Project has collected and analyzed data on drug resistance from
surveys of sampled patients and from national surveillance systems from an ever increasing
number of settings around the world [7].
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The review of Cohn et al, 1997 represented a comprehensive description of worldwide drug
resistance surveys performed during the 1990s. According to the study, resistance to multiple
drugs varied by geographic region and was more common when resistance was acquired
rather than primary. The rate of multidrug resistance (and occasionally other drugs) was low
in most surveys of primary resistance, ranging from 0 to 10.8% (median rate, 0.5%); however,
for acquired resistance, the rate of multidrug resistance ranged from 0 to 48.0% (median rate,
12.2%). For surveys that did not distinguish between primary and acquired resistance, the
range was 0.5% to 14.3% (median rate, 2.3%). In terms of antituberculous drug resistance, they
found a great deal of variability between different countries, and within some countries,
differences between regions or cities [13].
The review of Caminero et al of 2010 [14], broadly discuss the epidemiological data of the
global report, issued in 2008. The report included drug susceptibility data from 90 726 patients
in 83 countries and territories from year 2002 to 2007. The median prevalence of resistance in
new cases of TB was 11.1% for any drug and 1.6% for MDR-TB. The prevalence of MDR-TB in
new TB cases ranged from 0% in eight countries to 22.3% in Baku, Azerbaijan, and 19.4% in
the Republic of Moldova. Of the 20 settings with the highest proportion of MDR-TB in new
cases, 14 were located in countries of the former Soviet Union (between 6.8% and 22.3% in nine
countries, including Moldovia and Azerbaijan) and four in China (7% in two provinces in
China) [15, 16], A trend analysis of the 2008 report shows that between 1994 and 2007 the
prevalence of MDR-TB in new cases (initial resistance) increased substantially in South Korea
and two Russian Oblasts, Tomsk and Orel. By contrast, the prevalence remained stable in
Estonia and Latvia, both of which have high rates of initial MDR-TB. The prevalence of MDR-
TB in all TB cases decreased in Hong Kong and the United States [14].
Of 37 countries and territories that reported representative data on XDR-TB, five countries, all
from the former Soviet Union, each reported 25 or more cases of XDR-TB, with MDR-TB
prevalence ranging from 6.6% to 23.7% [15, 16], data from Eastern Mediterranean countries
showed that the prevalence of initial MDR-TB was higher than previously estimated, with the
exception of Morocco and Lebanon, with rates of respectively 0.5% and 1.1%. Initial MDR-TB
rates in Jordan and Yemen were respectively 5.4% and 2.9%. The Americas, Central Europe
and Africa reported the lowest rates of initial MDR-TB, with the notable exceptions of Peru,
Rwanda and Guatemala, which reported rates of respectively 5.3%, 3.9% and 3.0%. [15, 16].
Data on previously treated cases from the WHO/ Union 2008 report were available for 66
countries and two regions of China [15]. Drug susceptibility testing (DST) results were
available for 12 977 patients. Resistance to at least one anti-tuberculosis drug ranged from 0%
in three European countries to 85.9% in Tashkent, Uzbekistan. The highest proportions of
MDR-TB were reported in Tashkent (60.0%) and Baku, Azerbaijan (55.8%). data from Gujarat
State, India, providing the first reliable descriptions of previously treated cases in India,
showed 17.2% MDR-TB in this group [15].
The 2008 WHO/Union report also included a global estimation of the MDR-TB problem [14].
Based on drug resistance data from 114 countries and two regions of China reporting to this
project, combined with nine other epidemiological factors, the proportion of MDR-TB among
new, previously treated and combined cases was estimated for countries with no survey
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information available. The estimated proportion of MDR-TB for all countries was then applied
to incident TB cases (also based on indirect estimates). It was calculated that 4 89 139 (95%
confidence limits [95%CL] 455 093–614 215) cases emerged in 2006, and that the global
proportion of MDR-TB among all cases was 4.8% (95%CL 4.6–6.0). India, China and the Russian
Federation were estimated to have the highest number of MDR-TB cases: India and China have
approximately 50% of the global burden and the Russian Federation a further 7%. Twenty
seven countries accounted for 86% of the world’s MDRTB burden [14].
Caminero et al, divided the world into four large regions according to the influence of the three
factors i.e., past and present management of TB and transmission of MDR-TB.
1. Countries with an epidemic: high prevalence and incidence of MDR-TB.
2. Countries with high MDR-TB prevalence but low or decreasing incidence.
3. Countries with low prevalence and incidence of MDR-TB and
4. Countries with low prevalence but an increasing incidence of MDR-TB.
The fourth edition of WHO Guidelines for surveillance of drug resistance in tuberculosis is an updat‐
ed version of earlier editions published in 1994, 1997 and 2003. These guidelines incorporate the
2007 WHO Interim recommendations for the surveillance of drug resistance in tuberculosis and the
conclusions of an Expert Committee Meeting on Anti-Tuberculosis Drug Resistance Surveys
held in Geneva in September 2008. In addition experience gained from 15 years of the Global
Project on Anti-Tuberculosis Drug Resistance Surveillance is also included [7].
Given below are some of the updates and clarifications in surveillance methodology that have
been incorporated into the 4th edition:
1. At a minimum, surveillance should evaluate susceptibility to the following drugs:
a. Isoniazid and rifampicin;
b. If resistance is detected to rifampicin, then susceptibility to the fluoroquinolones and
second- line injectable agents most often used in the setting have be tested. Testing for
susceptibility to the first-line drug ethambutol should also be considered.
2. Statistical and epidemiological methodology is a fundamental aspect of designing surveys
that sample patients, and appropriate technical assistance should be received in the early
stages of planning. In particular, for surveys that use cluster-based sampling methods,
results should be adjusted to correct for biases introduced by these sampling techniques.
Missing values should also be accounted for, e.g. using multiple imputation techniques
when possible.
3. MDR-TB management is a component of the Stop TB Strategy and WHO Member States
have committed themselves to achieve universal access to diagnosis and treatment by
2015. Therefore, all drug resistance surveillance activities should be linked to patient
treatment and care. Planning a comprehensive treatment programme for patients
identified during a survey as having drug-resistant TB should run in parallel to planning
the survey itself.
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3.2. MDR-TB and immigration
Gilad et al [9] assessed the incidence of TB in Southern Israel in the period between 1992
and 1997,  and studied the prevalence of  resistance to anti-TB drugs and its  distribution
among the various subpopulations inhabiting that region, with the intention of tailoring
the empirical anti-TB treatment guidelines to those subpopulations. This study described
the  unique epidemiology of  drug-resistant  TB in  Southern Israel,  a  region inhabited by
both native and immigrant populations. Significant differences in age, gender, and resist‐
ance rates were found among the four distinct  subpopulations inhabiting the Negev re‐
gion.  They  attributed  the  observed  differences  to  immigration  from  countries  of  high
prevalence  of  drug-resistant  TB.  According  to  an  earlier  10-year  survey  (1978-  1987)  of
TB in the Negev,  Ethiopian immigrants and Bedouin Arabs comprised 76% of  TB cases
and 33% of them were extrapulmonary TB [17]. However the study of Gilad et al [9], re‐
corded only 20% of  isolates as  extrapulmonary,  and Ethiopian immigrants and Bedouin
Arabs comprised only 40% of the cases. These differences demonstrate how dynamic this
disease might be,  tremendously influenced by immigration, and demonstrate the impor‐
tance of continued surveillance in such a setup [9].
A worldwide survey of drug resistance rates by the WHO [18] demonstrated high rates
of resistance among isolates in the former Soviet  Union,  with the highest  rates detected
in Latvia. The Resistance rates observed rom the study for the immigrants from the for‐
mer  Soviet  Union  (IFSU)  were  much  higher  than  those  encountered  in  the  Russian  re‐
public  for  every  drug  or  drug  combination  [9].  These  rates  were  very  similar  to  those
found in Latvia, and were even higher overall (50% and 41.5%, respectively). In this cur‐
rent  era,  import  of  infectious  diseases  across  international  borders  occurs  much readily
[9].  The studies done in Germany and Canada also had reported an increased incidence
of multidrug resistance due to the immigration [19-21].
These studies have shown the impact of immigration on the incidence and distribution of drug-
resistant TB in a particular country and the importance of continuous surveillance and
immediate therapeutic decisions to prevent the dissemination of such resistant strains to their
general populations [9].
3.3. HIV and MDR-TB
The epidemiological impact of HIV on the epidemic of drug-resistant TB is not known and
may depend on several factors. HIV-positive TB cases are more likely to be smear negative. In
addition, delayed diagnosis of drug resistance and unavailability of treatment (particularly in
previous years) have led to high death rates in people living with HIV. Both of these factors
(smear negativity and short duration of disease due to mortality) may suggest a lower rate of
general transmission. However, HIV-positive cases progress more rapidly to disease and in
settings where MDR-TB is prevalent (either in the general population or in the local population
such as a hospital or a district), this may lead to rapid development of a pool of drug-resistant
TB patients or an outbreak [7].
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According to Cohn et al, 1997 [13], though the association of MDR-TB with AIDS has been well
documented during outbreaks [22-24], the role of HIV infection as a risk factor for the devel‐
opment of drug-resistant TB in other settings was not clear [25]. In Kenya, Malawi, Tanzania,
COte d'Ivoire, and France, drug resistance was not associated with HIV infection [26-30]. In
contrast, in a survey of eight metropolitan areas of the United States, HIV infection was
associated with resistance to antituberculous drugs, both within and outside the New York
City area [31]. The acquired MDR-TB also occurs in largely immunocompetent hosts, which
was seen in India, Korea, Nepal, and Bolivia [32-35].
The  studies  by  Borrell  and  Gagneux  [36]  pointed  out  that,  from  a  scientific  point  of
view, the actual evidence for primary transmission of MDR -TB in HIV-negative individ‐
uals that has been confirmed by molecular methods is very limited, and that more stud‐
ies including molecular data are needed to know the true extent of primary MDR-TB &
XDR –TB in a general population.
3.4. Inadequate treatment and development of MDR and XDR-TB
Multidrug-resistant  tuberculosis  (MDR-TB)  is  a  major  challenge  for  TB  control  world‐
wide.  Inadequate treatment  of  MDR-TB inevitably results  in high mortality  and the de‐
velopment  of  XDR-TB  [37].  The  study  of  Jeon  et  al,  2011  [38],  shows  how  inadequate
treatment has contributed to the high prevalence of MDR and XDR-TB in Korea. Accord‐
ing to  Jeon et  al,  the three TB referral  hospitals  in  the public  sector  are  responsible  for
the management of MDR-TB in the public sector of Korea. This study showed poor out‐
come for  patients  with  MDR-TB at  the  3  TB  hospitals  in  Korea:  low treatment  success
rate (37.1%),  high default  rate (37.1%),  and high all-cause mortality rate (31.2 %) during
the  3-4  yr  after  treatment  initiation.  Since  the  National  Tuberculosis  Program (NTP)  of
Korea has focused on new cases, there have been limited nationwide data about the inci‐
dence and prevalence of MDR-TB and its treatment outcomes. Treatment success rate of
their study was the lowest ever reported among MDR-TB cohorts in Korea [38].
4. Molecular epidemiology of MDR-TB
4.1. Molecular epidemiology
Many different definitions of molecular epidemiology have been published and all mention
the use of molecular tools, but not all explicitly mention epidemiology. Molecular epidemiol‐
ogy is not just molecular taxonomy, phylogeny, or population genetics but the application of
these techniques to epidemiologic problems [39]. Epidemiology attempts to identify factors
that determine disease distribution in time and place, as well as factors that determine disease
transmission, manifestation, and progression. Further, epidemiology is always motivated by
an opportunity or possibility for intervention and prevention [39]. What distinguishes
molecular epidemiology is both the “molecular,” the use of the techniques of molecular biology
to characterize nucleic acid- or amino acid-based content, and the “epidemiology,” the study
of the distribution and determinants of disease occurrence in human populations [39].
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Molecular epidemiology makes use of the genetic diversity within strains of infectious
organisms to track the transmission of these organisms in human populations and to evaluate
the host and parasite -specific risk factors for disease spread.
Therefore molecular epidemiologic techniques can be incorporated into almost any epide‐
miologic assessment to improve exposure and outcome measures
4.2. Molecular epidemiology of TB
The molecular epidemiologic approach to studying tuberculosis epidemiology has identified
several new observations that could not have been obtained by conventional epidemiologic
or laboratory approaches [39]. Mycobacterial strain typing by means of molecular methods
has become an important instrument for tuberculosis surveillance, control and prevention [40].
Among DNA fingerprinting methods which restriction fragment length polymorphism
(RFLP) typing is the most common method used has permitted novel investigations of the
epidemiology and pathogenesis of tuberculosis. The use of IS6110, an insertion sequence which
is present in Mycobacterium tuberculosis, is generally considered to be the gold standard for
tuberculosis molecular epidemiology studies [41], but other molecular typing techniques could
be used as adjuncts in selected circumstances [42].
Spoligotyping is a technique based on the polymorphism of the direct repeat (DR) locus present
in M. tuberculosis DNA. The DR sequences are composed of multiple 36bp copies, interspersed
by short non repetitive sequences [43]. The direct-repeat locus in M. tuberculosis contains 10 to
50 copies of a 36-bp direct repeat, which are separated from one another by spacers that have
different sequences. However, the spacer sequences between any two specific direct repeats
are conserved among strains. Because strains differ in terms of the presence or absence of
specific spacers, the pattern of spacers in a strain can be used for genotyping (spacer oligonu‐
cleotide typing, or "spoligotyping"). Spoligotyping has two advantages over IS6110-based
genotyping. As small amounts of DNA are required, it can be performed on clinical samples
or on strains of M. tuberculosis shortly after their inoculation into liquid culture. In addition
the results of spoligotyping, which are expressed as positive or negative for each spacer, can
be expressed in a digital format. However, spoligotyping has less power to discriminate among
M. tuberculosis strains than does IS6110-based genotyping.
Mycobacterial interspersed repeat units (MIRU) genotyping categorizes the number and size
of the repeats in each of 12 independent MIRUs, with the use of a polymerase-chain-reaction
(PCR) assay, followed by gel electrophoresis to categorize the number and size of repeats in
12 independent loci, each of which has a unique repeated sequence. Two to eight alleles are at
each of the 12 loci, yielding approximately 20 million possible combinations of alleles. The
discriminatory power of MIRU genotyping is almost as great as that of IS6110-based geno‐
typing. Unlike IS6110-based genotyping, MIRU analysis can be automated and can thus be
used to evaluate large numbers of strains, yielding intrinsically digital results that can be easily
catalogued on a computer data base.
The PGRS, the DR and the GTG repeated sequences have mainly been used for sub typ‐
ing strains for which differentiation by IS6110  finger printing appeared insufficient. This
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is  useful  when M. tuberculosis  strains contain no or lesser than six copies of  IS6110.  Ac‐
cording to  a  recorded study in  Sri  Lanka,  68% of  the  isolates  had less  than five  copies
which were similar to that of other countries in the Asian region, such as India, Malay‐
sia, Oman and Hong Kong [44].
The study by Ghebremichael et al [45] determined the transmission pattern of TB strains in
Sweden. By MIRU-VNTR 31 (45%) of the 69 patients with Beijing strains were found in
altogether 7 clusters (2–11 per cluster), yielding 45 different patterns. Thus the MIRU-VNTR
typing, with fewer and larger clusters, was less discriminatory than IS6110 RFLP. The two
strains where a possible epidemiological linkage was established differed in one allele and
thus did not cluster in MIRU-VNTR. All strains that clustered by MIRU-VNTR were identical
also by RD deletions, mutT gene polymorphism and Rv3135 gene analysis, but not by
spoligotyping and IS1547. Four of the IS6110 RFLP clusters contained isolates that differed by
MIRU-VNTR. The combination of MIRUVNTR with RFLP resulted in the disappearance of
two clusters, and a reduction of the number of isolates in two clusters, compared to the
clustering observed with IS6110 RFLP clustering alone. In this study they found that patients
with DR Beijing strains have been diagnosed for more than a decade in Sweden. The majority
of the patients were foreign born, and their country of origin reflects areas where the Beijing
genotype is prevalent [45].
4.3. Molecular epidemiology of MDR-TB
A study by Calver et al [46], investigated an outbreak of tuberculosis using a molecular
epidemiologic approach and clinical and epidemiologic data to identify inadequacies in the
implemented DOTS-plus strategy that lead to the emergence of pre–XDR TB and XDR TB in
South Africa. They genotyped the drug-resistant M. tuberculosis isolates using molecular
techniques including insertion sequence (IS) 6110 RFLP, spoligotyping and MIRU typing (12-
loci format). Genotyping results indicated an on-going transmission of drug-resistant TB, and
contact tracing among case-patients in the largest cluster demonstrated multiple possible
points of contact. Phylogenetic analysis demonstrated stepwise evolution of drug resistance,
despite stringent treatment adherence. These findings suggested that existing TB control
measures in South Africa were inadequate to control the spread of drug-resistant TB in their
HIV co-infected population. Diagnosis delay and inappropriate therapy facilitated disease
transmission and drug resistance.
Hsu et al, 2010 [47], investigated the transmission and predominant genotypes of MDR- TB in
Eastern Taiwan using both spoligotyping and MIRU-VNTR. Of the tested MDR isolates of 73
(94%) Spoligotyping, identified the Beijing strain as the predominant genotype (n = 48, 66%),
followed by Haarlem H3 (n = 15, 21%), T1 (n = 3, 4%) and East-African Indian 2 MANILLA (n
= 1, 1%). Six (8%) isolates did not match any spoligotype in the SpolDB4 database. Using MIRU-
VNTR typing, they observed a unique pattern in 27 isolates, and 46 had clustered pattern
strains (10 clusters). According to them by MIRU-VNTR they observed an isolate in cluster 9,
however from spoligotyping, it had a unique pattern and therefore they did not considered it
as a clustered pattern strain. By considering both spoliotyping and MIRU-VNTR into account,
28 (38.4%) isolates were judged to have a unique pattern and 45 (61.6%) were clustered pattern
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strains (classifying into 10 clusters). Assuming that there was one source case in each cluster
and the rest in the cluster were due to transmission, Hsu et al, concluded that 47.9% ([45 − 10]/
73) of the patients had MDR-TB due to recent transmission [47].
To better understand the epidemiology of MDRTB, the New York City Tuberculosis Control
Program began DNA genotyping of MDRTB strains from new cases in 1995 [48]. The objectives
of the study were to provide descriptive molecular epidemiology of MDRTB cases in the city
during 1995–1997 and to identify predominant MDR strains present during the three years, as
well as the extent and risk factors for clustering among the tested cases. Genotyping results
were available for 234 patients; 153 (65.4%) were clustered, 126 (82.3%) of them in eight clusters
of >4 patients. Epidemiologic links were identified for 30 (12.8%) patients; most had been
exposed to patients diagnosed before the study period. From the analysis, the largest cluster
observed was from the “W” strain (59 patients) representing almost 25% of the 241 MDRTB
patients during the 3 years. This strain caused a well-documented multi-institutional outbreak
in New York City from 1990 through 1993 [49-53]. Strain “W1”, which was isolated in seven
patients, is a variant of the W strain. It had an additional IS6110 copy and was a part of the W
strain outbreak [52, 53]. Forty percent (12 of 30) of the epidemiologic links in this cohort were
to patients with these two strains. According to Munsiff et al [48] these strains were likely
transmitted in the early 1990s when MDRTB outbreaks and tuberculosis transmission were
widespread in New York.
To analyze the molecular epidemiology of M. tuberculosis strains at a hospital in Buenos Aires,
Argentina, and mutations related to MDR and XDR-TB, Gonzalo et al [54], conducted a
prospective case –control study. Spoligotyping identified predominance of the Haarlem family
among the MDR TB cases (family responsible for the 1990s [55] outbreak) as well as the LAM
and T families. A similar strain family distribution was reported for the French Departments
of the Americas [56] and Turkey [57]. The Beijing family was seldom encountered in these
areas, which is in line with recent observations in 7 countries in South America, including
Argentina [58]. According to them [54] the MDR TB Haarlem2 strain appears to be more
successful than other circulating MDR- TB strains and also than its susceptible counterpart (of
25 Haarlem2 strains, 20 were MDR TB).
By genotyping all isolates and combining with the mutational results, Perdigão et al [59] were
able to assess the isolates' genetic relatedness and determine possible transmission events.
According to their study strains belonging to family Lisboa, characterized several years ago,
were responsible for the majority of the MDR-TB. Even more alarming was the high prevalence
of extensive drug-resistant tuberculosis (XDR-TB) among the MDR-TB isolates, which was
found to be 53%.
4.4. Transmission of MDR-TB and XDR-TB
Mathematical models predict that the future of the multidrug-resistant (MDR) and extensively
drug-resistant (XDR) tuberculosis (TB) epidemic will depend to a large extent on the trans‐
mission efficiency or relative fitness of drug-resistant Mycobacterium tuberculosis compared to
drug-susceptible strains. Molecular epidemiological studies comparing the spread of drug-
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resistant to that of drug-susceptible strains have yielded conflicting results: MDR strains can
be up to 10 times more or 10 times less transmissible than pan-susceptible strains [36].
Experimental work performed with model organisms has highlighted a level of complexity in
the biology of bacterial drug resistance that is generally not considered during standard
epidemiological studies of TB transmission. However, much more work is needed to under‐
stand the detailed molecular mechanisms and evolutionary forces that drive drug resistance
in this pathogen. Such increased knowledge will allow for better epidemiological predictions
and assist in the development of new tools and strategies to fight drug resistant TB [36].
In infectious disease epidemiology, the relevant measure that reflects the reproductive fitness
of a pathogen is the number of secondary cases generated; this measure is also known as the
basic reproductive rate, R0 [60]. In addition to the absolute number of secondary cases (i.e.,
absolute fitness), an often more useful measure is that of ‘relative fitness’, where the success
of a particular pathogen variant is compared to the success of another. For example, the fitness
of a drug-resistant bacterial strain can be expressed relative to the fitness of a drug-susceptible
strain. In addition to epidemiological measures of relative fitness, differences in relative fitness
can be measured experimentally [36].
The results of experimental studies performed with strains resistant to INH, SM or RMP
suggested that, in clinical settings, there was a strong selection pressure for drug resistance-
conferring mutations that cause minimal fitness defects [61]. Although these findings support
the notion that virulence and competitive fitness assays can be predictive of the epidemiology
of drug-resistant TB, they do not capture the overall complexity of the life cycle of M. tuber‐
culosis [36]. Although several mechanisms of compensatory evolution have been described in
other bacteria [62] little work has been done on this topic in M. tuberculosis.
Various molecular tools have been developed to genotype M. tuberculosis strains [63]. These
tools have been applied to molecular epidemiological investigation of TB transmission for
many years. According to the standard concept, patient isolates sharing a particular genotype
or DNA ‘fingerprint’ can be considered epidemiologically linked and represent cases of active
TB transmission (i.e., they are clustered TB cases), whereas strains with distinct or ‘unique’
DNA patterns are thought to reflect reactivation of latent infections. They compared molecular
epidemiological fitness estimates from two previous reviews and more recent studies [60, 64].
Overall, the relative fitness estimates for MDR-TB vary dramatically, ranging from an almost
10-fold increased fitness compared to fully drug-susceptible strains found in a study from
Russia [65] to about 10-fold lower fitness in Mexico [66] other studies have reported that MDR
strains do not cause any secondary cases at all [67]. The reasons for this high variability in
relative fitness of MDR strains have likely to do with the differences in study design and
setting, differences in sample size and different methodologies and also to the variation in the
quality of the TB control programmes [36]. According to Borrell and Gagneux, in addition to
methodological, socio-economic and environmental factors, the variation in MDR fitness also
reflects biological heterogeneity. Current epidemiological evidence for transmission of MDR-
and XDR-TB, particularly compared to pan-susceptible TB, is very inconclusive. This can be
partially explained by the fact that M. tuberculosis is more genetically diverse than is often
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appreciated [68] and because drug-resistant strains can exhibit heterogeneous fitness com‐
pared to drug-susceptible strains [36].
5. Conclusion
An understanding of the epidemiology of multidrug resistant tuberculosis (MDR-TB) and the
extensively drug-resistant tuberculosis (XDR-TB) is critical for effective control of the global
burden of tuberculosis (TB). For a comprehensive study on epidemiology of multidrug
resistant tuberculosis (MDR-TB), please refer the reviews in the reference list.
6. Future studies
Future Studies on Epidemiology
In all epidemiological studies it is essential to have a clear definition of a case of the disease
being investigated by delineating the symptoms, signs or other characteristics indicating that
a person has the disease. A clear definition of an exposed person is also necessary. This
definition must include all the characteristics that identify a person as being exposed to the
factor in question. In the absence of clear definitions of disease and exposure, it is very difficult
to interpret the data from an epidemiological study.
Future Studies on Transmission of TB
Future epidemiological studies on the transmission of drug-resistant TB should incorporate
more comprehensive strain data, including specific drug resistance-conferring mutations and
information on the strain genetic background. These variables, as well as their interaction,
could play an important role in the transmission success of particular drug-resistant variants.
Future Studies on HIV/TB
The investigators who conduct the studies on HIV/ TB need to consider other possible risk
factors for drug resistance such as demographics; prior therapy, socioeconomic status, and
quality of TB control programs, etc.
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